Axonal damage and loss of connectivity in nigrostriatal and mesolimbic dopamine pathways in early Parkinson's disease

被引:96
|
作者
Caminiti, Silvia Paola [1 ,2 ]
Presotto, Luca [2 ]
Baroncini, Damiano [3 ]
Garibotto, Valentina [4 ]
Moresco, Rosa Maria [5 ,6 ]
Gianolli, Luigi [7 ]
Volonte, Maria Antonietta [3 ]
Antonini, Angelo [8 ,9 ]
Perani, Daniela [1 ,2 ,7 ]
机构
[1] Univ Vita Salute San Raffaele, Via Olgettina 58, I-20132 Milan, Italy
[2] Ist Sci San Raffaele, Div Neurosci, Via Olgettina 58, I-20132 Milan, Italy
[3] Osped San Raffaele, Dept Neurol, Via Olgettina 60, I-20132 Milan, Italy
[4] Univ Geneva, Geneva Univ Hosp, Dept Med Imaging, Geneva, Switzerland
[5] IBFM CNR, Segrate, Italy
[6] Univ Milano Bicocca, Dept Hlth Sci, Tecnomed Fdn, Monza, Italy
[7] Osped San Raffaele, Nucl Med Unit, Via Olgettina 60, I-20132 Milan, Italy
[8] IRCCS Hosp San Camillo, Parkinsons Dis & Movement Disorders Unit, Via Alberoni 70, I-30126 Venice, Italy
[9] Univ Padua, Dept Neurosci DNS, Via Giustiniani 5, I-35128 Padua, Italy
关键词
Parkinson's disease; Positron emission tomography; Dopamine transporter; Axonal damage; Molecular connectivity; VENTRAL TEGMENTAL AREA; POSITRON-EMISSION-TOMOGRAPHY; FUNCTIONAL CONNECTIVITY; SUBSTANTIA-NIGRA; BRAIN; TRANSPORTER; PET; DISORDERS; PATHOLOGY; NETWORKS;
D O I
10.1016/j.nicl.2017.03.011
中图分类号
R445 [影像诊断学];
学科分类号
100207 ;
摘要
A progressive loss of dopamine neurons in the substantia nigra (SN) is considered the main feature of idiopathic Parkinson's disease (PD). Recent neuropathological evidence however suggests that the axons of the nigrostriatal dopaminergic system are the earliest target of a-synuclein accumulation in PD, thus the principal site for vulnerability. Whether this applies to in vivo PD, and also to the mesolimbic system has not been investigated yet. We used [C-11]FeCIT PET to measure presynaptic dopamine transporter (DAT) activity in both nigrostriatal and mesolimbic systems, in 36 early PD patients (mean disease duration in months +/- SD 21.8 +/- 10.7) and 14 healthy controls similar for age. We also performed anatomically-driven partial correlation analysis to evaluate possible changes in the connectivity within both the dopamine networks at an early clinical phase. In the nigrostriatal system, we found a severe DAT reduction in the afferents to the dorsal putamen (DPU) (eta(2) = 0.84), whereas the SN was the less affected region (eta(2) = 0.31). DAT activity in the ventral tegmental area (VTA) and the ventral striatum (VST) were also reduced in the patient group, but to a lesser degree (VST eta(2) = 0.71 and VTA eta(2) = 0.31). In the PD patients compared to the controls, there was a marked decrease in dopamine network connectivity between SN and DPU nodes, supporting the significant derangement in the nigrostriatal pathway. These results suggest that neurodegeneration in the dopamine pathways is initially more prominent in the afferent axons and more severe in the nigrostriatal system. Considering PD as a disconnection syndrome starting from the axons, it would justify neuroprotective interventions even if patients have already manifested clinical symptoms.
引用
收藏
页码:734 / 740
页数:7
相关论文
共 50 条
  • [1] Nigrostriatal dopamine transporter availability in early Parkinson's disease
    Fazio, Patrik
    Svenningsson, Per
    Cselenyi, Zsolt
    Halldin, Christer
    Farde, Lars
    Varrone, Andrea
    MOVEMENT DISORDERS, 2018, 33 (04) : 592 - 599
  • [2] Impaired finger dexterity and nigrostriatal dopamine loss in Parkinson’s disease
    S. H. Lee
    M. J. Lee
    C. H. Lyoo
    H. Cho
    M. S. Lee
    Journal of Neural Transmission, 2018, 125 : 1333 - 1339
  • [3] Impaired finger dexterity and nigrostriatal dopamine loss in Parkinson's disease
    Lee, S. H.
    Lee, M. J.
    Lyoo, C. H.
    Cho, H.
    Lee, M. S.
    JOURNAL OF NEURAL TRANSMISSION, 2018, 125 (09) : 1333 - 1339
  • [4] Nigrostriatal and Mesolimbic D2/3 Receptor Expression in Parkinson's Disease Patients with Compulsive Reward-Driven Behaviors
    Stark, Adam J.
    Smith, Christopher T.
    Lin, Ya-Chen
    Petersen, Kalen J.
    Trujillo, Paula
    Van Wouwe, Nelleke C.
    Kang, Hakmook
    Donahue, Manus J.
    Kessler, Robert M.
    Zald, David H.
    Claassen, Daniel O.
    JOURNAL OF NEUROSCIENCE, 2018, 38 (13) : 3230 - 3239
  • [5] Relationship between neuromelanin and dopamine terminals within the Parkinson's nigrostriatal system
    Martin-Bastida, Antonio
    Lao-Kaim, Nicholas R.
    Roussakis, Andreas Antonios
    Searle, Graham E.
    Xing, Yue
    Gunn, Roger N.
    Schwarz, Stefan T.
    Barker, Roger A.
    Auer, Dorothee P.
    Piccini, Paola
    BRAIN, 2019, 142 : 2023 - 2036
  • [6] Nigrostriatal dopamine-independent resting-state functional networks in Parkinson's disease
    Ham, Jee Hyun
    Cha, Jungho
    Lee, Jae Jung
    Baek, Gwang-Min
    Sunwoo, Mun Kyung
    Hong, Jin Yong
    Shin, Na-Young
    Sohn, Young Ho
    Lee, Jong-Min
    Lee, Phil Hyu
    NEUROIMAGE, 2015, 119 : 296 - 304
  • [7] Onset pattern of nigrostriatal denervation in early Parkinson's disease
    Pineda-Pardo, Jose A.
    Sanchez-Ferro, Alvaro
    Monje, Mariana H. G.
    Pavese, Nicola
    Obeso, Jose A.
    BRAIN, 2022, 145 (03) : 1018 - 1028
  • [8] Effect of methamphetamine self-administration on tyrosine hydroxylase and dopamine transporter levels in mesolimbic and nigrostriatal dopamine pathways of the rat
    Jack D. Shepard
    David T. Chuang
    Yavin Shaham
    Marisela Morales
    Psychopharmacology, 2006, 185 : 505 - 513
  • [9] Dopamine Synthesis in the Nigrostriatal Dopaminergic System in Patients at Risk of Developing Parkinson's Disease at the Prodromal Stage
    Blokhin, Victor
    Pavlova, Ekaterina N.
    Katunina, Elena A.
    Nodel, Marina R.
    Kataeva, Galina V.
    Moskalets, Elina R.
    Pronina, Tatiana S.
    Ugrumov, Michael V.
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (03)
  • [10] Effect of methamphetamine self-administration on tyrosine hydroxylase and dopamine transporter levels in mesolimbic and nigrostriatal dopamine pathways of the rat
    Shepard, JD
    Chuang, DT
    Shaham, Y
    Morales, M
    PSYCHOPHARMACOLOGY, 2006, 185 (04) : 505 - 513